Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort

Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort

Background: Vedolizumab (VDZ) for subcutaneous (SC) injection was approved for use in Europe in 2020 and the US in 2023. Promising efficacy and tolerability have been proven in pivotal trials. However, real-world data on the SC use of VDZ, especially in patients with active disease, are still lackin...

Full description

Bibliographic Details
Main Authors: Alica Kubesch, Nina Kruse, Florian Jungheim, Ümniye Balaban, Katharina Stratmann, Kathrin Sprinzl, Antje Dienethal, Thomas Krause, Stefan Zeuzem, Irina Blumenstein
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Journal of Clinical Medicine
Subjects:
IBD
Crohn’s disease
ulcerative colitis
biologics
real-world data
vedolizumab
Online Access:https://www.mdpi.com/2077-0383/12/24/7657

Internet

https://www.mdpi.com/2077-0383/12/24/7657

Similar Items